Last reviewed · How we verify
Diacerhein
At a glance
| Generic name | Diacerhein |
|---|---|
| Sponsor | Laboratoires NEGMA |
| Target | Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Diacerein in Psoriasis Vulgaris (PHASE4)
- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (PHASE2, PHASE3)
- Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (NA)
- A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis (PHASE2)
- Efficacy of Diacerein Supplementation on Interleukin-1β, Hs-CRP, TNF-α Levels and Glycemic Control in Uncontrolled Type 2 Diabetes Mellitus Patients at Dr. Mohammad Hoesin General Hospital Palembang (PHASE2, PHASE3)
- Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients (PHASE3)
- Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers (PHASE1)
- Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diacerhein CI brief — competitive landscape report
- Diacerhein updates RSS · CI watch RSS
- Laboratoires NEGMA portfolio CI